GlobalData on MSN7h
GSK stays optimistic on vaccines amidst US and China woes
While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth.
GSK outlines 2025 growth driven by specialty medicines and new product launches
Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...
FiercePharma9h
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
European Shares Flat as Tech Losses Counter Healthcare Boost
(Reuters) - European shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo ...
Business Times16h
GSK plans £2 billion share buyback, boosts long-term outlook
GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its ...
The Making Of A Great Healthcare Brand: Mayo Clinic
To understand how the Mayo Clinic became a superior healthcare brand, I talked with Leonard Berry, PhD, to understand their ...